Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk

Food and Healthcare Press Releases Wednesday December 6, 2017 15:01
ABU DHABI, UAE--6 Dec--PRNewswire/InfoQuest
  • Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1]
  • 1 in 3 respondents considered themselves to be at low risk of CVD[2]
  • 1 in 6 respondents had never discussed type 2 diabetes and cardiovascular risk with a healthcare professional[2]
  • The Taking Diabetes to Heart global online survey for people with type 2 diabetes was presented at the IDF Congress 2017 in Abu Dhabi

Today the International Diabetes Federation (IDF) presented the interim results of the first ever multi-country online survey on CVD risk awareness and knowledge among people living with type 2 diabetes, indicating low levels of awareness and limited dialogue between patients and healthcare professionals. The global survey - Taking Diabetes to Heart - developed in partnership with Novo Nordisk, runs until March 2018 and is open to all people with type 2 diabetes.

Diabetes currently affects 425 million adults worldwide[1], with most cases being type 2 diabetes. Cardiovascular disease, which includes stroke, coronary heart disease and peripheral artery disease[3], is the leading cause of disability and death in people with type 2 diabetes[1],[4].

To date, 943 responses to the survey have been received from 32 countries and interim findings show that:
  • 1 in 3 respondents living with type 2 diabetes consider their risk of CVD to below[2]
  • 26% of respondents had either never learned about CVD or received information on CVD several years following their type 2 diabetes diagnosis[2]
  • 1 in 6 respondents had never discussed their type 2 diabetes and CVD risk with a healthcare professional[2]

"The interim results of Taking Diabetes to Heart reiterate the importance of raising awareness of the association between type 2 diabetes and cardiovascular disease to promote prevention, timely diagnosis and appropriate treatment to help reduce the current burden that the two conditions represent," said Dr Shaukat Sadikot, outgoing IDF President. "With the world facing an increase in the prevalence of type 2 diabetes, better understanding the link between these conditions is needed more than ever."

Taking Diabetes to Heart - http://www.idf.org/takingdiabetes2heart/survey - aims to gather insights on current gaps in education and CVD risk behaviour among people with type 2 diabetes, and to put in place advocacy and patient support strategies and tactics to improve health and wellbeing among populations.

"Cardiovascular disease is the leading cause of disability and death among people living with type 2 diabetes. Too few individuals with diabetes are being informed by healthcare professionals of their cardiovascular risk and the impact that risk may have on their longevity and quality of life," said Alan Moses, senior vice president and chief medical officer of Novo Nordisk. "We encourage more people in the diabetes community to complete the Taking Diabetes to Heart survey to strengthen the global findings that will inform future efforts to help improve outcomes."

The results of Taking Diabetes to Heart will serve to define the actions that are required to improve the health outcomes of people with type 2 diabetes. The initiative will culminate in a comprehensive report with country-specific results and resources to help support knowledge and awareness of CVD among people with type 2 diabetes around the world.

For more information about Taking Diabetes to Heart, visit http://www.idf.org/takingdiabetes2heart . For more information about diabetes and CVD, visit http://www.idf.org/cvd
About the International Diabetes Federation

The International Diabetes Federation (IDF) is an umbrella organisation of over 230 national diabetes associations in 165 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950. The Federation's activities aim to influence policy, increase public awareness and encourage health improvement, promote the exchange of high-quality information about diabetes, and provide education for people with diabetes and their healthcare providers. IDF is associated with the Department of Public Information of the United Nations and is in official relations with the World Health Organization (WHO). http://www.idf.org .

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.com , Facebook, Twitter, LinkedIn, YouTube.

Taking Diabetes to Heart

Taking Diabetes to Heart - http://www.idf.org/takingdiabetes2heart - consists of an online survey available in multiple languages, including Arabic, Bulgarian, Chinese, Danish, Dutch, English, French, Filipino, Finnish, German, Hindi, Italian, Portuguese, Russian, Spanish, Swahili and Vietnamese. The survey will remain online until March 2018. Results from the survey will be used to inform policy and decision-making around this common and serious complication of diabetes.[2],[3]

Further information
Media:
Katrine Sperling         +45 4442 6718   krsp@novonordisk.com
Asa Josefsson           +45 3079 7708   aajf@novonordisk.com
Investors:
Peter Hugreffe Ankersen +45 3075 9085   phak@novonordisk.com
Hanna Ogren             +45 3079 8519   haoe@novonordisk.com
Anders Mikkelsen         +45 3079 4461   armk@novonordisk.com
Christina Kjaer           +45 3079 3009   cnje@novonordisk.com
Kasper Veje (US)         +1 609 235 8567 kpvj@novonordisk.com
IDF Media:
Lorenzo Piemonte         +32 495 797 936 lorenzo.piemonte@idf.org
Suvi Karuranga           +32 267 955 88   suvi.karuranga@idf.org
References
1. International Diabetes Federation. IDF Diabetes Atlas, 8th Edition. Brussels, Belgium: International Diabetes Federation, 2017. Available at: http://www.diabetesatlas.org
2. International Diabetes Federation, 2017. Taking Diabetes to Heart - Global IDF survey on CVD risk awareness among people with diabetes. Available at: http://www.idf.org/takingdiabetes2heart
3. International Diabetes Federation. Diabetes and Cardiovascular Disease. Brussels, Belgium: International Diabetes Federation, 2016. Available at: http://www.idf.org/cvd
4. World Health Organization, editor. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2009. 62p.
Source: Novo Nordisk

Latest Press Release

Whisk#s AI-Powered Culinary Coach Named as Winner of Ascensia Diabetes Challenge

Today, at the American Diabetes Association's 78th Scientific Sessions in Orlando, Florida, Ascensia Diabetes Care has revealed that UK-based Whisk have been selected as the winner of the Ascensia Diabetes Challenge, a global innovation competition that...

Significant Blood Sugar Improvement With Xultophy(R) Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications

Adults with type 2 diabetes treated with Xultophy(R) (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks Xultophy(R) (insulin degludec and liraglutide...

Tresiba(R) Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study

Adults with type 2 diabetes treated with Tresiba(R) (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE)...

Ozempic(R) Provided Greater Weight Reductions for Adults With a Baseline BMI ?25kg/m2 Than Those With Lower Baseline BMI 25kg/m2, in a SUSTAIN 7 Post-hoc Analysis

Ozempic(R) (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass index (BMI), with the greatest reductions occurring in adults...

Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial

Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the PIONEER 1 phase 3a trial. The trial evaluated...

Related Topics